scispace - formally typeset
Search or ask a question
Topic

Growth factor receptor inhibitor

About: Growth factor receptor inhibitor is a research topic. Over the lifetime, 4730 publications have been published within this topic receiving 297500 citations.


Papers
More filters
Journal ArticleDOI
TL;DR: This anti-apoptotic function of IGF-1 may be important to the development of follicle cells as follicles undergo a growth cycle where the regressive, catagen phase is apoptosis driven.
Abstract: Insulin-like growth factor 1 (IGF-1) has been identified as an important growth factor in many biological systems[1] It shares considerable structural homology with insulin and exerts insulin-like effects on food intake and glucose metabolism Recently it has been suggested to play a role in regulating cellular proliferation and migration during the development of hair follicles [2,3] To exert its biological effects, the IGF-1 is required to activate cells by binding to specific cell-surface receptors The type I IGF receptor (IGF-1R) is the only IGF receptor to have IGF-mediated signaling functions[1] In circulation, this growth factor mediates endocrine action of growth hormone (GH) on somatic growth and is bound to specific binding proteins (BPs) The latter control IGF transport, efflux from vascular compartments and association with cell surface receptors[4] In tissues, IGF-1 is produced by mesenchymal type cells and acts in a paracrine and autocrine fashion by binding to the IGF-1R This binding activates the receptor tyrosine kinase (RTK) that triggers the downstream responses and finally stimulates cell division[5] IGF-1 may therefore be able to stimulate the proliferation of hair follicle cells through cellular signaling pathways of its receptors Local infusion of IGF-1 into sheep has been reported to be capable of stimulating protein synthesis in the skin[6] It may also increase the production of wool keratin Recently, transgenic mice overexpressing IGF-1 in the skin have been shown to have earlier hair follicle development than controls[7] In addition, this growth factor plays an important role in many cell types as a survival factor to prevent cell death[8] This anti-apoptotic function of IGF-1 may be important to the development of follicle cells as follicles undergo a growth cycle where the regressive, catagen phase is apoptosis driven In this review, the effects of IGF-1 on follicle cell proliferation and differentiation are discussed In particular, the paracrine versus endocrine action of IGF-1 on hair growth and the targeting of expression of the growth factor to the follicles of transgenic animals will be emphasized The anti-apoptotic role of IGF-1 in hair follicles is also reviewed Prospects for future studies on hair and fiber growth by IGF-1 are discussed

101 citations

Journal ArticleDOI
TL;DR: It is concluded that pro-HB- EGF has unique biological activity through cell-cell contact that is distinct from the activity of sHB-EGF and that the cytoplasmic domain of EGFR is essential for pro- HB-EGf-induced apoptosis.

101 citations

Journal ArticleDOI
TL;DR: The results indicate that PDGF-B, which is involved in the maintenance of microvessels, plays a more important role in angiogenesis in intestinal-type gastric carcinomas than VEGF-A, which plays a key role mainly in the initiation of new blood vessel formation.
Abstract: Background Angiogenesis is important in the growth and metastasis of various kinds of solid tumors, including gastric cancers. The angiogenic process is triggered by several key growth factors, including vascular endothelial growth factor (VEGF)-A and platelet-derived growth factor (PDGF)-B, that are secreted by tumors. Our aim was to define: i) the expression pattern of VEGF-A and PDGF-B in tumor cells and the activation of PDGF receptor (PDGFR)-β tyrosine kinase in stromal cells of human gastric adenocarcinomas; and ii) the relationship between VEGF-A and PDGF-B expression and microvessel density (MVD), to determine if there is a rationale for a new therapeutic strategy.

101 citations

Journal ArticleDOI
TL;DR: The combined usage of sVEGFR plus sFGFR1 suppressed tumor growth in all cancer cell lines tested, suggesting possible effectiveness of this strategy against a wide range of cancers.
Abstract: Anti-tumor angiogenesis therapy using soluble receptors: enhanced inhibition of tumor growth when soluble fibroblast growth factor receptor-1 is used with soluble vascular endothelial growth factor receptor

101 citations

Journal ArticleDOI
TL;DR: Sarcomas are good candidates for the design of a clinical study targeting insulin-like growth factor-I receptor, and an attention to schedule with chemotherapy agents and new drugs, measurement of relevant indicators of response and better molecular understanding of the metabolic functions of insulin- like growth factors receptor and its functional relationship with insulin receptor are necessary to proceed safely with theDesign of anti-insulin-likegrowth factor strategies.
Abstract: PURPOSE OF REVIEW The present review examines the rationale for targeting insulin-like growth factor-I receptor in sarcoma therapy and highlights some key issues that need to be addressed as clinical trials targeting insulin-like growth factor-I receptor proceed. RECENT FINDINGS Preclinical evidence supports proof of principle for targeting insulin-like growth factor-I receptor signaling in sarcomas. The insulin-like growth factor system is activated by or associated with most of the fusion oncoproteins that genetically characterize a group of sarcomas, but alterations in this pathway appear as a common feature. Correlation of cancer risk with insulin-like growth factor-I receptor signaling expression and polymorphisms has also been described. Blockade of insulin-like growth factor-I receptor functions results in an inhibition of tumor growth and metastasis, both when the targeted drugs were used as single agents and in combined therapies. Antibodies against insulin-like growth factor-I receptor and small kinase inhibitors represent, at this point, the most probable clinical options. SUMMARY Sarcomas are good candidates for the design of a clinical study targeting insulin-like growth factor-I receptor. An attention to schedule with chemotherapy agents and new drugs, measurement of relevant indicators of response and better molecular understanding of the metabolic functions of insulin-like growth factor-I receptor and its functional relationship with insulin receptor are necessary to proceed safely with the design of anti-insulin-like growth factor strategies.

101 citations


Network Information
Related Topics (5)
Cancer
339.6K papers, 10.9M citations
88% related
Signal transduction
122.6K papers, 8.2M citations
86% related
Apoptosis
115.4K papers, 4.8M citations
86% related
Cell culture
133.3K papers, 5.3M citations
85% related
Breast cancer
214.3K papers, 6.4M citations
85% related
Performance
Metrics
No. of papers in the topic in previous years
YearPapers
202352
20225
20211
20201
20191
201811